Global ADME-Toxicology Testing Market 2016-2024 with Profile of 69 Key and Niche Players - Research and Markets

DUBLIN, June 21, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "ADME-Toxicology Testing - Global Strategic Business Report" report to their offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for ADME-Toxicology Testing in US$ by the following Segments: Toxicology Testing (In-Vivo, In-Vitro), and ADME Testing. Market data and analytics are derived from primary and secondary research.

The report profiles 69 companies including many key and niche players such as

• ACEA Biosciences, Inc. (USA)
• ADMEcell, Inc. (USA)
• Agilent Technologies, Inc. (USA)
• Albany Molecular Research, Inc. (USA)
• Beckman Coulter, Inc. (USA)
• BioreclamationIVT, LLC (USA)
• Cerep SA (France)
• CompuDrug International, Inc. (USA)
• Cyprotex PLC. (UK)
• CeeTox, Inc. (USA)
• Dassault Systèmes Biovia Corp. (USA)
• Eurofins ADME BIOANALYSES SAS (France)
• Galapagos NV (Belgium)
• Molecular Discovery Ltd. (UK)
• MultiCASE, Inc. (USA)
• Optivia Biotechnology (USA)
• PerkinElmer, Inc. (USA)
• Pharmaron, Inc. (USA)
• Promega Corporation (USA)
• Qualyst, Inc. (USA)
• Simulations Plus, Inc. (USA)
• Taconic Biosciences, Inc. (USA)
• Takara Bio Europe AB (Sweden)
• Tecan Group Ltd. (Switzerland)
• Thermo Fisher Scientific, Inc. (USA)

Key Topics Covered:

1. OUTLOOK

• ADME-Tox Testing Gains Traction
• A Peek into the Impact of ADME-Tox Screening on New Drug Discovery
• Current and Future Analysis
• US and Europe Dominate, Asia-Pacific Lends Growth Momentum
• Growth Momentum Shifts Away from In Vivo Technologies; In Vitro Technologies to Lead the Charge

2. INDUSTRY OVERVIEW

• Pharma Industry Renews Focus on Cost Optimization
• ADME-Tox Assays
• Introduction of Early In Vitro ADMET Studies
• Growing Prominence of Cell-based Assays in Drug Discovery and ADME Analysis
• Major Types of Cell-Based HTS Assays for Drug Screening
• CROs Expand Presence
• Drug Discovery Outsourcing and Type of Services Outsourced
• Changing Face of Drug Discovery Outsourcing Activity
• M&A
• Order of the Day

3. MARKET DYNAMICS

• Current State of ADME-Tox Testing
• Need for Better Models: A Major Factor Driving Innovation in the Market
• Focus Shifts to Innovative Approaches
• In Silico and In Vitro- the Way to Go
• In Vitro Testing Systems and Its Relevance in Drug Development
• Growing Inclination towards In-vitro Assays for Toxicology Studies
• In Silico ADME-Tox Growing at a Fast Clip
• Advantages of Using In Silico Approaches
• Factors Hindering Growth
• 3-D Tissue Bioassays to Enhance In Vitro Toxicity Testing
• Increasing Use of Cell-Based Assays over Other Methods in Toxicity Testing
• Rising Number of Drug Targets Surge Demand for Cell-Based Assays
• Growing Focus on the Development of Reproducible and Robust Cell-based Assays
• Functional Assays: An Effective Way of Predicting Specific Toxic Effects 

4. DRUG DISCOVERY & DEVELOPMENT

• Drug Discovery and Development
• Target identification
• Target Validation
• Lead Identification
• Lead Optimization
• Pharmaceuticals
• R&D Value Chain
• Pre-Clinical Testing
• Clinical Trials
• Clinical Trials
• The Time Line
• Drug Discovery Technologies
• Innovation in Screening Guarantees Success for Drug Discovery Programs

5. PRODUCT OVERVIEW

• ADME-Tox
• An Introduction
• Absorption
• Distribution
• Metabolism
• Excretion
• Toxicity
• ADME-Tox Profiling
• ADME-Tox Screening Technologies
• ADME-Tox Parameters
• Cell Based Assays
• Liver Cell Based Assays
• Intestinal Cell Based Assays
• Kidney Cell Based Assays

6. PRODUCT INNOVATIONS/INTRODUCTIONS

• Corning Adds Two New Products to ADME/Tox Lineup
• Sovicell and 3B Pharmaceuticals Launch EScalate Assay Service
• Lonza Launches Human and Animal Hepatocytes for Adme-Tox Testing
• Cyprotex Launches Eight New Transporter Assays
• Simulations Plus Rolls Out Version 8.0 of ADMET Predictor Software
• Simulations Plus Launches Version 7.2 of ADMET Predictor Software
• BioReliance® Unveils Select In Vitro ADME and Toxicology Testing Services
• Cyprotex Releases SenCeeTox® Technology with Enhanced Capabilities
• Cyprotex Expands In-House Drug Transporter Services
• Cyprotex Launches KeratinoSens Service
• Simulations Plus Introduces ADMET Predictor Version 7.1
• Lena Biosciences Launches SeedEZ 3D Cell Culture Products
• Sigma® Life Science to Introduce Genetically-Modified HepaRG Human Liver Cell Line

7. RECENT INDUSTRY ACTIVITY

• Simulations Plus to Take Over DILIsym Services
• Simulations Plus and Electrolab India Sign Distribution Deal
• Simulations Plus Inks Distribution Deal with Quantum Bio Solutions for Korean Market
• Cyprotex Moves to New Location in the UK
• Pharmaron Takes Over Xceleron
• Evotec Acquires Cyprotex
• Endonovo Expands Cytotronics Platform for Toxicology Testing
• Takara Bio Acquires Cellectis AB
• WuXi PharmaTech Acquires XenoBiotic Laboratories
• Merck KGaA to Take Over Sigma-Aldrich
• Dassault Systèmes Acquires Accelrys
• Organovo Collaborates with J&J for 3D Bioprinting Drug Discovery Research
• Taconic and IVAL Enter into Agreement
• Charles River to Acquire Galapagos' Argenta and BioFocus Service Divisions
• Simulations Plus Signs 5-Year RCA with the US FDA
• Simulation Plus Inks Distributor Agreement with RILD
• Harlan CRS Enters into Strategic Alliance with Bertin Pharma
• Pharmaron Receives GLP Certification from the CFDA for GLP Toxicology Facilities
• Cyprotex Acquires CeeTox
• Taconic Announces Name Change
• Rosa & Co. Acquires Entelos Holdings' Consulting Service Business
• Thermo Fisher Scientific Acquires Life Technologies

8. FOCUS ON SELECT PLAYERS

9. GLOBAL MARKET PERSPECTIVE

For more information about this report visit https://www.researchandmarkets.com/research/k5jd3s/admetoxicology

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716